SG/PUT/VERTEX PHARMACEUTICALS/450/0.1/21.03.25

SG/PUT/VERTEX PHARMACEUTICALS/450/0.1/21.03.25 Stock

DE000SU6QSW2

Market Closed - Bid/Ask 13:09:49 2024-07-03 EDT			After market 14:13:02
2.77 ^EUR	+1.09%		2.84	+2.53%

Current month	-4.20%
1 month	-24.52%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart SG/PUT/VERTEX PHARMACEUTICALS/450/0.1/21.03.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	07-02	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	07-02	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	CI

More news

Quotes 5-day view

Date	Price	Change
24-07-03	2.77	+1.09%
24-07-02	2.74	-2.49%
24-07-01	2.81	-1.75%
24-06-28	2.86	+3.25%
24-06-27	2.77	-1.42%

Real-time Boerse Frankfurt Warrants

Last update July 03, 2024 at 01:09 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Société Générale
WKN	SU6QSW
ISIN	DE000SU6QSW2
Date issued	2024-01-08
Strike	450 $
Maturity	2025-03-21 (261 Days)
Parity	10 : 1
Emission price	5.91 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	6.95 €
Lowest since issue	2.55 €
Delta	-0.33x
Omega	5.015
Premium	10.83x
Gearing	15.35x
Moneyness	0.9569
Difference Strike	-20.28 $
Difference Strike %	-4.51%
Spread	0.14 €
Spread %	4.81%
Theoretical value	2.840
Implied Volatility	31.02 %
Total Loss Probability	57.42 %
Intrinsic value	0.000000
Present value	2.840
Break even	419.38 €
Theta	-0.04x
Vega	0.13x
Rho	-0.12x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company